Stratos Investment Management LLC Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Stratos Investment Management LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 63.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 84,046 shares of the company's stock after acquiring an additional 32,559 shares during the quarter. Stratos Investment Management LLC's holdings in Novo Nordisk A/S were worth $5,836,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Victory Capital Management Inc. lifted its position in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after buying an additional 23,223 shares during the last quarter. North Star Investment Management Corp. increased its stake in Novo Nordisk A/S by 18.2% during the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock worth $1,440,000 after purchasing an additional 3,200 shares during the period. Stanley Laman Group Ltd. purchased a new stake in Novo Nordisk A/S during the first quarter worth about $390,000. Dover Advisors LLC purchased a new stake in Novo Nordisk A/S during the first quarter worth about $505,000. Finally, Natural Investments LLC purchased a new stake in Novo Nordisk A/S during the fourth quarter worth about $1,345,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent research reports. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. BNP Paribas initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating on the stock. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Stock Down 3.0%

Shares of NVO stock traded down $2.17 during trading hours on Friday, reaching $68.85. 3,191,136 shares of the stock were exchanged, compared to its average volume of 9,241,162. The business's fifty day moving average is $70.36 and its two-hundred day moving average is $75.21. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $143.49. The firm has a market capitalization of $307.39 billion, a P/E ratio of 20.37, a P/E/G ratio of 1.36 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. As a group, research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.